Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mabgenex Common Krait antivenom monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- Mabgenex
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Mabgenex is developing a monoclonal antibody-based therapeutic for the treatment of Common Krait (*Bungarus caeruleus*) envenomation. This preclinical-stage program aims to replace traditional animal-derived polyclonal antivenoms with highly specific, recombinant monoclonal antibodies discovered using the company's machine learning-driven platforms, PrecinAb and OptinAb. The antibodies are designed to neutralize the potent neurotoxins in the venom that cause respiratory paralysis. The development is supported by the Biotechnology Industry Research Assistance Council (BIRAC) through a Biotechnology Ignition Grant (BIG). This approach represents a modern alternative to traditional antivenoms, aiming to reduce the risk of adverse reactions like serum sickness and anaphylaxis while providing standardized potency.
- Other names
- Snake Anti-Venom ProgramCommon Krait venom monoclonal antibody
02
Targets
LαNTx (Common Krait long-chain three-finger alpha-neurotoxins)
Beyond the preview
Go deeper on Mabgenex Common Krait antivenom monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mabgenex Common Krait antivenom monoclonal antibody.